An analogue
peptide that comprises the variable regions of the light or heavy chains of an
antibody of a first species selectively binding to a
carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an
effector agent and / or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for
in vivo imaging and treating a primary or metastasized
carcinoma, and
in vitro diagnosing a
carcinoma,
ex vivo purging neoplastic cells from a
biological fluid. RNAs and DNAs
encode the analogue
peptide, and a
hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue
peptide. An anti-
idiotype polypeptide comprises
polyclonal antibodies raised against an anti-carcinoma
antibody or the analogue peptide of this invention,
monoclonal antibodies thereof, Fab, Fab′, (Fab′)2, CDR, variable region, or analogues or fragments thereof, combinations thereof with an
oligopeptide comprising a TRP
trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-
idiotype hybrid polypeptide with an
effector agent and the anti-
idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma
vaccination kit, a method of vaccinating against carcinoma and a method of lowering the
serum concentration of a circulating
antibody or polypeptide are provided.